Top 8 Frequently Asked Questions About MultiOmyx
MultiOmyx is a highly multiplexed immunofluorescent (IF) imaging technology capable of spatially quantifying up to 60 biomarkers from a single slide. In addition to profiling protein biomarkers, the same slide can be analyzed using FISH and/or NGS and similarly MultiOmyx IF technology can be combined with RNAscope, enabling a comprehensive multi-omic interrogation of protein, DNA, RNA and mutational profiling from a single slide.
Unlike ‘grind and find’ or limited multiplex technologies MultiOmyx provides powerful insight by enabling comprehensive phenotyping of protein, DNA, and RNA biomarkers, by combining additional “omics” capabilities from a single slide. Qualitative staining is transformed to quantitative analysis, enabling unambiguous cellular classification based on co-expression, and precise spatial context of diverse immune cells utilizing advanced spatial analytics. In the important field of immune-oncology, MultiOmyx enables deep interrogation of the interaction between immune cells and tumor biology.
MultiOmyx is provided as a fee-for-service solution for both research and clinical trial projects. Clients contract NeoGenomics’ Pharma Services team to perform either custom panel development or to utilize the standard MultiOmyx Tumor Infiltrating Lymphocyte Panel for comprehensive immunophenotyping from a single slide. The client defines a statement of work that is customized to their specific needs via detailed interaction with a dedicated project manager, samples are sent, analysis is performed and data returned to the client, in depth Pathologist and scientific review with client is maintained throughout the project. Samples can be received from the majority of global locations.
All projects are performed in a CLIA certified laboratory which is aligned to ISO 15189 and 21 CFR Part 11.
During our assay development process Pathologists and Scientists optimize the staining sequence to ensure that the multiplexed assay is equivalent to single plex staining.
Commonly MultiOmyx utilizes FFPE tissue, either whole tissue of TMA’s. A wide range of disease indications have been investigated using breast, colon, lung, liver tissue types. NeoGenomics can procure samples from commercial vendors if required.
NeoGenomics has an extensive list of over 100 antibodies which have been utilized in MultiOmyx, typically monoclonal antibodies are down selected from a number of commercial vendors and characterized for use by both Pathologist and Scientist evaluation as comparable with IHC results. NeoGenomics routinely introduces new antibodies to offer the latest available biomarker selection in immune-oncology.
NeoGenomics utilizes a wide range of proprietary bio-image informatics analysis algorithms to quantitate individual biomarker expression and co-expression of biomarkers as a standard dataset.